Contents
KTRL and delay sprays create different routines: a spray applies a formulation, while KTRL WDC201 adds rhythmic physical sensation through an external patch. Some sprays contain local anaesthetics that reduce sensitivity. Compare the exact ingredients, preparation, partner-contact precautions and usable cost. A product format alone does not guarantee more time or establish that two products can be combined.
By KTRL | Updated:13 October 2026
KTRL vs delay sprays: compare the whole routine
Start with the experience you want and the instructions you can follow. A sensitivity-reducing formulation and an added rhythmic sensation serve different purposes; comparing their handling does not make their effects equivalent.
KTRL Portable Smart Patch, model WDC201, is a single-use consumer electronic sensory product for men aged 18–60, inclusive. It is not a medical device and is not intended to diagnose, treat, alleviate, monitor or prevent a disease or medical condition. Its user guide defines its placement, material and use restrictions.
Practical differences between a delay spray and KTRL WDC201QuestionDelay sprayKTRL WDC201Sensation approachDepends on the formulation; some reduce sensitivity.Adds rhythmic physical sensation.PreparationProduct-specific amount, application area, waiting and removal.Clean, dry, intact skin; instructed placement and activation.Skin contactAn applied formulation.Conductive gel and TPE insulating foam.Partner contactCheck transfer and contact precautions.No separate spray layer; consent and comfort still matter.Protective roleNot a condom or a contraceptive method.No pregnancy or STI protection.Next occasionFollow storage, expiry and permitted-use instructions.A fresh patch is required.Sources: the Fortacin EU product information, EAU clinical guidance and the KTRL guide. A named spray's details do not apply to every spray, and this table is not a ranking of safety or effectiveness.
What the Fortacin EU label tells you
Fortacin provides a specific example of why the exact label matters. The European Medicines Agency (EMA) overview identifies it as a lidocaine/prilocaine spray indicated for primary, or lifelong, premature ejaculation in adult men. This EU indication does not establish Mexican authorisation, availability or the instructions for another spray.
EMA lists the linked product-information document as last updated on3 February 2025. Read the current leaflet for the product actually supplied to you. In Mexico, a qualified local pharmacist can help check the exact pack and locally applicable information; an EU document is not a Mexican product label.
Preparation includes waiting and wiping
The Fortacin label defines one dose as three sprays to the glans, with at least four hours between doses and no more than three doses in 24 hours. It specifies waiting five minutes and then wiping off excess before intercourse. Wiping is still required when a condom is used. Patient leaflet, pages 25–26
These are facts about this named label, not a stand-alone dosing guide. The leaflet also explains priming before first and subsequent use, handling and other conditions. Follow the complete instructions; do not transfer the dose, timing or removal routine to another spray or a cream.
Partner transfer and condom materials need separate checks
The label warns that transfer to a partner can cause temporary local numbness and mask normal pain sensations. That makes removal and contact precautions relevant even when the intended effect is reduced sensitivity. Discuss them with your partner before use.
Fortacin must not be used with polyurethane male or female condoms, because deterioration was observed. Its product information allows contraceptive devices made of latex rubber, polyisoprene, nitrile or silicone. Those material statements belong to Fortacin; they do not establish compatibility for every spray or cancel its wiping requirement. Product-information warnings, pages 3–4
Allergies and other medicines still matter
Fortacin is contraindicated if the user or partner has the specified allergies, including hypersensitivity to its active ingredients, other ingredients or amide-type local anaesthetics. The full leaflet also covers health conditions, other medicines and unwanted effects. Check these with a pharmacist or doctor where relevant; applying a medicine to skin does not mean there can be no systemic effects or interactions.
The EAU guideline provides broader clinical context for topical anaesthetics. It does not establish KTRL efficacy or compatibility with a spray. Persistent or distressing ejaculation concerns are a reason for professional assessment, rather than repeatedly changing formats without addressing the concern.
KTRL preparation and the question of combined use
KTRL requires correct patch placement and monitoring, with no separately measured spray. It has built-in non-rechargeable power, but its conductive gel and TPE insulating foam still contact the skin. The absence of an applied spray does not establish greater safety or a treatment benefit.
Keep track of the patch's cumulative time
Before use, check suitability and the package, prepare the designated clean, dry, intact external skin, and follow the placement and button instructions. The maximum is 30 minutes of cumulative powered-on time during the same use. Switched-off intervals do not count, and restarting continues the existing total. Monitor the time; do not assume an automatic timer. WDC201 instructions
For poor adhesion or a position adjustment during the same use, switch off before removal. This does not allow storage for a later occasion or another session with the used patch. Stop immediately for pain, stinging, burning, redness, swelling, itching or other obvious discomfort; switch off and gently remove the patch. If discomfort persists, discontinue further use and consult a qualified professional.
The first-use checklist gives the full process and restrictions. The single-use explanation covers short-use and reuse questions.
Can you combine a delay spray with KTRL?
Do not assume compatibility from different application areas. KTRL must not be used when treatment or medicines may affect skin sensation, local reactions or judgement about safe use. A numbing product is not exempt simply because it is topical. A pharmacist can clarify the exact spray's ingredients and warnings, but professional advice does not override either product's prohibited-use conditions.
Do not apply spray beneath the patch or wet its contact area with a topical formulation. Each product's application area, partner-contact rules and material restrictions still apply. If the instructions conflict or suitability cannot be established, do not combine them; separate positions do not demonstrate safety or a combined benefit.
Compare cost per usable dose or patch
The useful denominator is the number of permitted doses you will actually use before the applicable discard date. Container size or dose capacity alone can make the cost look lower than it will be.
Spray cost per used dose = delivered container cost ÷ permitted doses actually used before the applicable discard date. For Fortacin, the label states that a 6.5 mL container delivers at least 20 doses and a 5 mL container at least 12 doses. These are minimum delivery counts, not maximum capacities, and a dose is not the same as one spray. Pack sizes and shelf life, page 11
The same label says to discard the container 12 weeks after first use. That period does not start at purchase or delivery, and it does not override printed expiry or other limits. Record first use so you can judge how much will realistically be used. Do not increase use to empty a container or calculate a different dose from its volume.
A hypothetical budget in Mexican pesos
The following prices and quantities are invented budgeting assumptions, prepared on10 October 2026. They are not live prices, evidence of Mexican availability or recommendations about how often to use a medicine.
Hypothetical spending, in MXNAssumptionCalculationEffective costA 20-dose spray container costs MXN 600 delivered; all 20 permitted doses are used before the applicable discard date.MXN 600 ÷ 20MXN 30 per used dose.The same container is bought, but only five permitted doses are used before that date.MXN 600 ÷ 5MXN 120 per used dose.A separate three-patch pack costs MXN 360 delivered; all three patches are usable and used.MXN 360 ÷ 3MXN 120 per patch.Source: the stated hypothetical assumptions and arithmetic. These figures compare cash spending, not equivalent effects. Replace them with the actual label, pack, expiry, delivered price and realistic use frequency. The single-use versus reusable cost comparison covers the broader ownership model.
Frequently asked questions
Choose by the experience you want and the preparation and contact precautions you and your partner can follow. For other categories, see the product-format comparison; for spreadable formulations, see the cream comparison.
Does every delay spray follow the Fortacin routine?
No. The ingredient combination, dose, priming, contact precautions and waiting or removal steps belong to the exact product. A shared spray format does not make instructions interchangeable.
Does using a condom remove the need to wipe off Fortacin?
No. The Fortacin leaflet still requires wiping off excess after the five-minute wait, including when using a condom. Its polyurethane restriction also remains; follow the full label for the exact product.
Does a container with at least 20 doses mean 20 sprays?
No. Fortacin's labelled dose contains three sprays. The “at least 20 doses” statement belongs to its 6.5 mL container; budget using permitted doses actually used before the relevant expiry or discard limit.
Does KTRL avoid every skin-contact concern because it is not a spray?
No. KTRL still uses skin-contact materials and has its own skin, health and use restrictions. A different sensory approach does not prove greater safety, a treatment benefit or suitability for combined use.
References
Sources checked on13 October 2026. The Fortacin example is EU product information; it does not establish Mexican authorisation or the instructions for another spray. None of these sources establishes a head-to-head comparison or compatibility between KTRL and a specific spray.
European Medicines Agency. Fortacin overview and authorisation scope. EU indication, product identity and linked documents.
European Medicines Agency. Fortacin product information, English PDF. EMA lists the document as last updated 3 February 2025. Pages 2–4 cover dose and warnings; page 11 covers container capacity and shelf life; pages 23–27 contain patient-leaflet information.
European Association of Urology. Disorders of Ejaculation, 2026 guidance. General clinical context for topical anaesthetics, including a separate lidocaine/prilocaine spray subsection.
KTRL. WDC201 user guide. Product identity, materials, restrictions, cumulative powered-on time and single-use rules. Its stated basis is the English 3c instructions, updated 22 May 2026, and confirmed website instructions.